文献速递妇科

代谢综合征与子宫内膜癌生存的前瞻性队列研究

Prospective cohort study of metabolic syndrome and endometrial cancer survival.
PubMed 文献 · Gynecol Oncol · 2020-06-27

基于加拿大阿尔伯塔省2002至2006年诊断为原发性子宫内膜癌的540例幸存者,随访至2019年3月20日,中位随访14.2年。代谢综合征(HR=1.98,95%CI=1.07-3.67)及腰围≥88 cm(HR=2.12,95%CI=1.18-3.80)与更差的总生存相关,腰围每增加5 cm与更差的无病生存相关(HR=1.11,95%CI=1.00-1.24)。

要点

  • 代谢综合征与子宫内膜癌幸存者更差的总生存相关(HR=1.98,95%CI=1.07-3.67)。
  • 腰围≥88 cm与更差的总生存相关(HR=2.12,95%CI=1.18-3.80)。
  • 腰围每增加5 cm与更差的无病生存相关(HR=1.11,95%CI=1.00-1.24)。

核心结论

  • 代谢综合征,尤其是中心性肥胖,与子宫内膜癌幸存者更差的总生存和无病生存相关。

研究设计与样本

  • 基于人群的病例对照研究中的病例队列,纳入2002至2006年在加拿大阿尔伯塔省诊断为原发性子宫内膜癌的540例幸存者,随访至死亡或2019年3月20日。
  • 基线采用面对面访谈、直接人体测量和空腹血样评估代谢综合征。
  • 代谢综合征定义为以下≥3项:腰围≥88 cm、空腹血糖≥100 mg/dL、甘油三酯≥150 mg/dL、高密度脂蛋白胆固醇<50 mg/dL及自报高血压。
  • 采用Cox比例风险回归和Fine and Gray竞争风险模型估计多变量校正风险比(95%CI)。

主要发现

  • 540例子宫内膜癌幸存者中,325例在诊断时存在代谢综合征,132例在中位14.2年随访(范围0.3-16.5年)内复发和/或死亡。
  • 诊断代谢综合征与更差的总生存相关(HR=1.98,95%CI=1.07-3.67)。
  • 腰围≥88 cm与更差的总生存相关(HR=2.12,95%CI=1.18-3.80),腰围每增加5 cm的HR=1.21(95%CI=1.07-1.36)。
  • 腰围每增加5 cm与更差的无病生存相关(HR=1.11,95%CI=1.00-1.24)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Comorbidities are known to increase endometrial cancer risk, but the separate and combined impact of these risk factors on endometrial cancer survival remains unclear. This study aimed to determine the associations between metabolic syndrome and its components with disease-free survival, overall survival, endometrial cancer-specific survival and recurrence among endometrial cancer survivors. METHODS: Cases from a population-based case-control study who were diagnosed with primary endometrial cancer between 2002 and 2006 in Alberta, Canada were followed until death or March 20, 2019. Baseline in-person interviews, direct anthropometric measurements and fasting blood samples were used to assess metabolic syndrome (presence of ≥3 of the following: waist circumference ≥ 88 cm, fasting blood glucose ≥100 mg/dL, triglycerides ≥150 mg/dL, high-density lipoprotein cholesterol <50 mg/dL and self-reported hypertension). Cox proportional hazards regression and Fine and Gray competing risk models were used to estimate multivariate-adjusted hazard ratios (95% CI) for these associations. RESULTS: Among 540 endometrial cancer survivors, 325 had metabolic syndrome at diagnosis and 132 had a recurrence and/or died during the median 14.2 years of follow-up (range: 0.3-16.5 years). In multivariable analyses, being diagnosed with metabolic syndrome (HR = 1.98, 95% CI = 1.07-3.67) and having an elevated waist circumference (≥88 cm; HR = 2.12, 95% CI = 1.18-3.80; HRper 5 cm = 1.21, 95% CI = 1.07-1.36) were associated with worse overall survival. Additionally, increasing waist circumference (per 5 cm) was also associated worse with disease-free survival (HRper 5 cm = 1.11, 95% CI = 1.00-1.24). CONCLUSION: The metabolic syndrome, in particular central adiposity, were associated with worse overall and disease-free survival in endometrial cancer survivors.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kokts-Porietis RL, McNeil J, Nelson G, et al. Prospective cohort study of metabolic syndrome and endometrial cancer survival. Gynecol Oncol. 2020. PMID: 32600790. doi:10.1016/j.ygyno.2020.06.488

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。